July 16, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide (Lipfendra), a novel macrocyclic peptide, is the first oral PCSK9 inhibitor FDA-approved to lower LDL, according to press releases from the company and the FDA.
710 words~3 min read
